HCP Home | Repatha.ca

Repatha® (evolocumab injection) is indicated:

  • as an adjunct to diet and standard of care therapy (including moderate- to high-intensity statin therapy alone or in combination with other lipid-lowering therapy) to reduce the risk of myocardial infarction, stroke and coronary revascularization in adult patients with atherosclerotic cardiovascular disease (ASCVD) by further lowering low-density lipoprotein cholesterol (LDL-C) levels
  • for the reduction of elevated LDL-C in adult patients with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH] and ASCVD): as an adjunct to diet and statin therapy, with or without other lipid-lowering therapies, in patients who require additional lowering of LDL-C; or as an adjunct to diet, alone or in combination with non-statin lipid-lowering therapies, in patients for whom a statin is contraindicated
  • as an adjunct to diet and other LDL-C-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in adult patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C

Consult the Product Monograph at www.amgen.ca/Repatha_PM.pdf or here for important information about:

  • Contraindications in patients with hypersensitivity to Repatha®, any ingredient in the formulation or component of the container; refer to contraindications for any concomitant lipid-lowering medications
  • Warnings and precautions regarding any concomitant lipid-lowering medications; hypersensitivity or serious allergic reactions; no studies in pregnant or nursing women; no information on presence in human milk, effects on milk production, effects on or risk to breastfed infants; discontinuation in pregnancy; severe renal impairment; severe hepatic impairment; latex-sensitive patients and SureClick ® autoinjector needle cap; uncertain effects in patients with/at risk of hepatitis C virus infection
  • Conditions of clinical use, adverse reactions, drug interactions and dosing

The Product Monograph is also available by calling Amgen Medical Information at 1-866-502-6436.

PCSK9i=proprotein convertase subtilisin/kexin type 9 inhibitor.
* Comparative clinical significance unknown.

Your account activation is pending further verification.

You will receive an email once the process is complete. Thank you for your patience.

You will redirect to login page automatically in 10 seconds.
Young woman giving an older man a bowl of food in a backyard setting
Heart organ

He looks to you to FOCUS ON RISK REDUCTION for MI, stroke, and coronary revascularization in adult patients with ASCVD

Prevention of cardiovascular events: Repatha® is indicated as an adjunct to diet and standard of care therapy (including moderate- to high-intensity statin therapy alone or in combination with other lipid-lowering therapy), to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adult patients with atherosclerotic cardiovascular disease (ASCVD) by further lowering low-density lipoprotein cholesterol (LDL-C) levels.1

Learn More

* Fictitious patient. May not be representative of all patients.
ASCVD=atherosclerotic cardiovascular disease; CV=cardiovascular; MI=myocardial infarction

Enrol your patients today

You are now leaving the Repatha.ca website

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to another Amgen Canada site?

Yes, leave Repatha.ca

You are now leaving the Repatha.ca website. Please note that these links are being provided as a convenience and for informational purposes only.

PROCEED